Many of our most potent cancer therapies—including radiotherapy, chemotherapy, photodynamic therapy (PDT), and chemodynamic therapy (CDT)—rely on a single, elegant mechanism of destruction: flooding the tumor cell with reactive oxygen species (ROS). When ROS levels surpass a critical threshold, they inflict catastrophic damage on DNA, proteins, and lipids, ultimately triggering programmed cell death or iron-dependent lipid peroxidation (ferroptosis).
Yet, clinical outcomes often fall short because malignant cells are moving targets. To survive in chronically stressful environments, tumors upregulate internal defense networks that act as a biochemical sponge. This elevated basal oxidative buffering capacity allows them to neutralize massive influxes of treatment-induced ROS, effectively shielding themselves from lethal damage.
To break this resistance, a major research direction focuses on a dual-action strategy: understanding the molecular architecture of this antioxidant shield and developing therapies that simultaneously generate oxidative stress while systematically dismantling the cell's ability to buffer it.
The Threshold of Oxidative Death
To understand why pro-oxidant therapies fail, we must look at the cell's internal redox equilibrium. A healthy cell maintains low levels of ROS. When a therapy like radiation hits the cell, it generates a spike in ROS. If that spike clears a certain threshold, the cell dies.
However, as demonstrated by Lili Song et al. in their study on chronic myeloid leukemia resistance, resistant cells often maintain an exceptionally low resting baseline of ROS by overexpressing scavenging enzymes like catalase [Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells]. This expanded buffering capacity means that a standard dose of a pro-oxidant drug, such as arsenic trioxide, gets absorbed by the cellular sponge before it can ever reach the lethal threshold.
Consequently, simply increasing the therapeutic dose of radiation or chemotherapy is rarely viable, as it introduces severe systemic toxicity. The solution lies in identifying the specific components of the shield and knocking them out.
The Molecular Architecture of the Shield
The tumor's antioxidant shield is multi-layered, consisting of microenvironmental scavengers, specialized enzymes, and master transcriptional regulators.
Glutathione: The Primary Chemical Shield
At the chemical level, the tripeptide glutathione (GSH) serves as the primary line of defense. High concentrations of GSH within the tumor microenvironment act as a direct biochemical shield, scavenging ROS before they can interact with vital cellular structures. As explored by Tingting Zhang et al., this microenvironmental abundance directly undermines the efficacy of combined chemo-photothermal treatments [A redox-activated theranostic nanoagent: toward multi-mode imaging guided chemo-photothermal therapy]. Similarly, Yang Peng et al. note that this high GSH concentration imposes a strict ceiling on the efficacy of manganese-mediated chemodynamic therapies by neutralizing radicals as soon as they are catalytically generated [Proton nanomodulators for enhanced Mn2+-mediated chemodynamic therapy of tumors via HCO3− regulation].
Enzymatic and Transcriptional Regulators
Beyond GSH, tumors rely on specific enzymatic machinery to process oxidative stress. For instance, Min Zhong et al. highlighted how cancer cells exploit the Thioredoxin Reductase 1 (TrxR1) enzyme to manage elevated ROS levels, identifying it as a critical vulnerability that can be targeted with organoselenium hybrids [Synthesis, cytotoxicity, antioxidant activity and molecular modeling of new NSAIDs-EBS derivatives].
At the genetic level, this entire defense apparatus is frequently orchestrated by the transcription factor NRF2 (encoded by the NFE2L2 gene). In an overview of glioma molecular mechanisms, the authors outline how tumors routinely hijack the Nrf2/KEAP1/ARE signaling axis to maintain redox homeostasis under the pressure of radiotherapy [Potential targets and treatments affect oxidative stress in gliomas: An overview of molecular mechanisms]. This upstream control is further reinforced by stabilizing enzymes. For example, Dian Zhang et al. discovered that the deubiquitinating enzyme USP35 directly stabilizes NRF2 in esophageal cancer cells, preventing its degradation and driving resistance to cisplatin chemotherapy [The deubiquitinating enzyme USP35 regulates the stability of NRF2 protein].
[USP35] ──(Stabilizes)──> [NRF2] ──(Activates)──> [Antioxidant Pathways (GSH, TrxR1, Catalase)]
│
▼
[Neutralizes Therapy-Induced ROS]
Metabolic Hijacking Fuels the Shield
Antioxidants cannot be synthesized without a steady supply of metabolic precursors. To sustain their high buffering capacity, tumor cells fundamentally rewire their core metabolism.
A prime example of this occurs in pancreatic cancer stem cells. Doudou Li et al. demonstrated that these highly resilient cells depend on a "non-canonical" glutamine metabolism pathway regulated by the transaminase GOT1 [Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy]. By routing glutamine through this pathway, the cells generate the NADPH necessary to keep their antioxidant pools in a reduced, active state. When the authors inhibited GOT1, the metabolic fuel line was severed, flooding the cells with unmitigated radiation-induced ROS.
On a systemic scale, the broader impact of circulating metabolites on redox balance is becoming clearer. In a large-scale Mendelian randomization study, the authors identified that specific blood metabolites and pathways regulating oxidative stress have a direct causal influence on the progression and chemoresistance of plasma cell malignancies like multiple myeloma [Causal effects of genetically determined blood metabolites on multiple myeloma: a Mendelian randomization study].
Lowering the Shield to Trigger Ferroptosis
The therapeutic value of dismantling these defenses is particularly evident in ferroptosis—a form of non-apoptotic cell death driven by the iron-dependent accumulation of lethal lipid peroxides. Because ferroptosis bypasses traditional apoptosis pathways, it represents a powerful tool to defeat drug-resistant cancers. However, its execution depends entirely on overwhelming the cell's lipid-protecting antioxidants, such as Glutathione Peroxidase 4 (GPX4).
Tumor cells frequently upregulate protective proteins to block this process. As reviewed by Chi Deng et al., high intracellular GSH levels directly feed GPX4, allowing tumors to survive severe lipid peroxidation pressures [Iron-based nanozymes induced ferroptosis for tumor therapy]. Overcoming these robust barriers requires targeted intervention. For example, Xue Liang et al. demonstrated that specific structural proteins, like CAV1, modulate the cellular susceptibility to lipid peroxidation, presenting a distinct hurdle when combining dietary interventions like a ketogenic diet with ferroptotic therapies [Integrative insights into the role of CAV1 in ketogenic diet and ferroptosis in pancreatic cancer].
To exploit this vulnerability, researchers are developing strategies to actively suppress these protective pathways:
- Signaling Axis Disruption: BIN CHEN et al. showed that knocking down the ribonucleotide reductase subunit RRM1 activates a p53-p21-GPX4 signaling axis. This genetic intervention strips away the cell's defenses, dramatically sensitizing tumors to radio- and chemotherapy-induced ferroptosis [Knockdown of RRM1 in tumor cells promotes radio-/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis].
- Biomimetic Co-delivery: Songhua Cai et al. engineered a biomimetic nanocarrier designed to deliver gene-silencing therapies alongside chemotherapeutics. By downregulating intrinsic antioxidant pathways, this platform amplifies ferroptosis and synergizes with anti-PD-L1 immunotherapy in lung cancer [Targeted tumor cell-intrinsic CTRP6 biomimetic codelivery synergistically amplifies ferroptosis and immune activation to boost anti-PD-L1 immunotherapy efficacy in lung cancer].
Designing Dual-Action Nanomedicines
The translation of this concept into practice has driven the development of multifunctional nanomedicines. Instead of relying solely on external ROS generation, modern nanoplatforms are engineered to act as "one-two punches": they catalyze Fenton or Fenton-like reactions to generate highly toxic hydroxyl radicals ($\cdot OH$) while simultaneously depleting the local antioxidant pool.
| Nanoplatform Strategy | ROS Generation Mechanism | Antioxidant Depletion Mechanism | Key Reference |
|---|---|---|---|
| Copper-Doped Silica | Catalyzes pH-dependent chemodynamic therapy (CDT) | Consumes local glutathione via redox reactions | Wanlan TANG et al. |
| Multifunctional Fenton Nanoagents | Triggers localized Fenton-like cascades | Buffers microenvironmental defenses to allow radical accumulation | Haiyan Gao et al. |
| Bioligand-Modified Mn MOFs | Enhances multi-enzyme catalytic cascades | Depletes internal tumor antioxidant capacity | Junfeng Ke et al. |
| Multienzyme-like MOFs (PyroFPSH) | Drives photodynamic therapy (PDT) generation of ROS | Scavenges and depletes intracellular glutathione | Letian Lv et al. |
The therapeutic logic behind these platforms is mathematically intuitive. If a nanozyme generates a substantial amount of ROS, but the tumor's local GSH concentration is high enough to neutralize it, the net therapeutic effect is zero.
By incorporating components that chemically react with and deplete GSH—such as the copper ions utilized by Wanlan TANG et al. [pH Responsive Copper-Doped Mesoporous Silica Nanocatalyst for Enhanced Chemo-Chemodynamic Tumor Therapy] or the multienzyme frameworks designed by Letian Lv et al. [Enhanced photodynamic therapy through multienzyme-like MOF for cancer treatment]—the nanomedicine forces the cell's buffering capacity to zero. Without its antioxidant shield, the tumor cell is entirely exposed to the therapeutic ROS cascade, lowering the required drug dose and effectively neutralizing therapeutic resistance.
Key Foundational Work
Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy (2015) — contributed 1 concept elements to this direction.
Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells (2014) — contributed 1 concept elements to this direction.